Efficacy and Safety of Donafenib in Patients With Previously Treated Metastatic Colorectal Cancer:a Controlled,Multicentre,Randomised, Phase 3 Trial

Trial Profile

Efficacy and Safety of Donafenib in Patients With Previously Treated Metastatic Colorectal Cancer:a Controlled,Multicentre,Randomised, Phase 3 Trial

Recruiting
Phase of Trial: Phase III

Latest Information Update: 24 Mar 2017

At a glance

  • Drugs Donafenib (Primary)
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Sponsors Suzhou Zelgen Biopharmaceuticals
  • Most Recent Events

    • 20 Mar 2017 Planned End Date changed from 1 Aug 2018 to 1 Dec 2018.
    • 20 Mar 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Aug 2018.
    • 20 Mar 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top